Dutch healthcare investor Jonghoud International and Industrial Bank of Taiwan Management's Boston Life Science fund are new investors in To-BBB's $5.5m B round, alongside existing investors Aescap Venture and Antea Participaties.
Netherlands-based drug delivery company To-BBB has raised €4m ($5.5m) in the first close of its series B round.
Dutch healthcare investor Jonghoud International and Industrial Bank of Taiwan Management’s Boston Life Science fund were new investors in the B round, alongside existing investors Aescap Venture and Antea Participaties.
Aescap had led To-BBB’s €4m A round in July 2007.
Willem van Weperen, chief executive of to-BBB, which has a G-Technology to distribute drugs to the brain, said: "The pharmaceutical…
